| Replacement Information | |
|---|---|
| Replacement Information | 07-1483 is a recommended replacement for AB3016. |
Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, M, R | WB, IH(P), ELISA, IP | Rb | Serum | Polyclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | 07-1483 |
| Replaces | AB3016 |
| Description | Anti-IκBα Antibody |
| Background Information | IKK beta (IκB Kinase, IKKβ, I-Kappa-B kinase-beta) is a member of the IKK complex which is composed of IKK alpha, IKK beta, IKK gamma and IKAP. IκB Kinase (IKK) complex is a critical component in NFκB regulation. In a majority of unstimulated cells, the NFκB transcription factors exist in their inactive form and are retained in the cytoplasm by the bound inhibitory IκB proteins. For NFκB to become activated, it must first disassociate from the inhibitor IκB. This occurs via the serine phosphorylation of IκB on Ser32 and Ser36. Post receptor stimulation, most notably by TNFα, NIK, a serine/threonine kinase, activates and phosphorylates IKKα and IKKβ. Phosphorylation of 2 sites at the activation loop of IKK beta is essential for activation of IKK by TNF and IL1. Once activated, IKK beta autophosphorylates, which in turn decreases IKK activity and prevents prolonged activation of the inflammatory response. Additionally, IKK beta activity can also be regulated by MEKK-1. IKK then binds to and phosphorylates IκBα on the two serine residues. This phosphorylation marks IκB for ubiquination and destruction by the proteosome. This frees the NFκB complex and allows it to translocate to the nucleus. |
| Product Information | |
|---|---|
| Format | Serum |
| Control |
|
| Presentation | Rabbit polyclonal IgG serum in buffer containing 0.02 M Potassium phosphate with 0.15 M NaCl, pH 7.2 and 0.1% sodium azide. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Detect IκBα using this Anti-IκBα Antibody validated for use in WB, IH(P), ELISA & IP. |
| Key Applications |
|
| Application Notes | Immunohistochemisty (paraffin): Representative testing from a previous lot. Anti-IкBα staining on invasive ductal carcinoma tissue (Breast Cancer) was pretreated with citrate buffer, pH 6.0. A 1:1,000 diluted was used using IHC-Select® detection with HRP-DAB. ELISA: Recommended Immunoprecipitation: Recommended Optimal dilutions must be determined by the end user. |
| Biological Information | |
|---|---|
| Immunogen | IκBα peptide corresponding to a region near the C-terminus of the human protein, conjugated to KLH. |
| Epitope | C-terminus |
| Host | Rabbit |
| Specificity | Recognizes IκBα, C-terminus. May react non-specifically with other proteins. Control peptide provided will compete only with the specific reaction of antiserum with IκBα. |
| Isotype | IgG |
| Species Reactivity |
|
| Antibody Type | Polyclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA (MIM 164014), or RELB (MIM 604758) to form the NFKB complex. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA or NFKBIB, MIM 604495), which inactivate NF-kappa-B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664, orIKBKB, MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G purine; and Y is a C or T pyrimidine).[supplied by OMIM]. |
| Gene Symbol |
|
| UniProt Number |
|
| UniProt Summary | FUNCTION: Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to tranlocate to the nucleus and activate transcription. SUBUNIT: Interacts with RELA; the interaction requires the nuclear import signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90 kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts with RWDD3; the interaction enhances sumoylation. SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles between the nucleus and the cytoplasm by a nuclear localization signal (NLS) and a CRM1-dependent nuclear export (By similarity). INDUCTION: Induced in adherent monocytes. PTM: Phosphorylated; disables inhibition of NF-kappa-B DNA-binding activity. PTM: Ubiquitinated; subsequent to stimulus-dependent phosphorylation on serines. PTM: Sumoylated; sumoylation requires the presence of the nuclear import signal. DISEASE: Defects in NFKBIA are a cause of autosomal dominant anhidrotic ectodermal dysplasia with immunodeficiency (AD-EDA-ID) [MIM:164008]. Ectodermal dysplasias (EDs) constitute a heterogeneous group of developmental disorders affecting tissues of ectodermal origin. EDs are characterized by abnormal development of two or more ectodermal structures such as hair, teeth, nails and sweat glands, with or without any additional clinical sign. Each combination of clinical features represents a different type of ectodermal dysplasia. SIMILARITY: Belongs to the NF-kappa-B inhibitor family. SIMILARITY: Contains 5 ANK repeats. |
| Molecular Weight | ~36 kDa |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Routinely evaluated by Western Blot on HEK293 lysates. Western Blot Analysis: 1:500 to 1:2,000 dilution of this lot detected IkBalpha on 10 μg of HEK293 lysates. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Both antibody and control are stable for 6 months at -20ºC in undiluted aliquots from date of receipt. Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. |
| Packaging Information | |
|---|---|
| Material Size | 100 µL |